Proton versus photon adjuvant radiotherapy: a multicenter comparative evaluation of recurrence following spinal chordoma resection
- PMID: 38691864
- DOI: 10.3171/2024.2.FOCUS23927
Proton versus photon adjuvant radiotherapy: a multicenter comparative evaluation of recurrence following spinal chordoma resection
Abstract
Objective: Chordomas are rare tumors of the skull base and spine believed to arise from the vestiges of the embryonic notochord. These tumors are locally aggressive and frequently recur following resection and adjuvant radiotherapy. Proton therapy has been introduced as a tissue-sparing option because of the higher level of precision that proton-beam techniques offer compared with traditional photon radiotherapy. This study aimed to compare recurrence in patients with chordomas receiving proton versus photon radiotherapy following resection by applying tree-based machine learning models.
Methods: The clinical records of all patients treated with resection followed by adjuvant proton or photon radiotherapy for chordoma at Mayo Clinic were reviewed. Patient demographics, type of surgery and radiotherapy, tumor recurrence, and other variables were extracted. Decision tree classifiers were trained and tested to predict long-term recurrence based on unseen data using an 80/20 split.
Results: Fifty-three patients with a mean ± SD age of 55.2 ± 13.4 years receiving surgery and adjuvant proton or photon therapy to treat chordoma were identified; most patients were male. Gross-total resection was achieved in 54.7% of cases. Proton therapy was the most common adjuvant radiotherapy (84.9%), followed by conventional or external-beam radiation therapy (9.4%) and stereotactic radiosurgery (5.7%). Patients receiving proton therapy exhibited a 40% likelihood of having recurrence, significantly lower than the 88% likelihood observed in those treated with nonproton therapy. This was confirmed on logistic regression analysis adjusted for extent of tumor resection and tumor location, which revealed that proton adjuvant radiotherapy was associated with a decreased risk of recurrence (OR 0.1, 95% CI 0.01-0.71; p = 0.047) compared with photon therapy. The decision tree algorithm predicted recurrence with an accuracy of 90% (95% CI 55.5%-99.8%), with the lowest risk of recurrence observed in patients receiving gross-total resection with adjuvant proton therapy (23%).
Conclusions: Following resection, adjuvant proton therapy was associated with a lower risk of chordoma recurrence compared with photon therapy. The described machine learning models were able to predict tumor progression based on the extent of tumor resection and adjuvant radiotherapy modality used.
Keywords: chordoma; decision tree; machine learning; radiation; resection; spine.
Similar articles
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
-
Optimizing radiotherapy strategies for skull base chordoma: a comprehensive meta-analysis and systematic review of treatment modalities and outcomes.Neurosurg Focus. 2024 May;56(5):E11. doi: 10.3171/2024.2.FOCUS2413. Neurosurg Focus. 2024. PMID: 38691862
-
Longitudinal treatment outcomes of recurrent clival chordomas: a single-center retrospective study.J Neurosurg. 2023 Oct 13;140(4):920-928. doi: 10.3171/2023.7.JNS231196. Print 2024 Apr 1. J Neurosurg. 2023. PMID: 37856417
-
Long-term outcome of primary clival chordomas: a single-center retrospective study with an emphasis on the timing of recurrences based on the primary treatment.Neurosurg Focus. 2024 May;56(5):E4. doi: 10.3171/2024.2.FOCUS23924. Neurosurg Focus. 2024. PMID: 38691852
-
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450. Health Technol Assess. 2007. PMID: 17999840
Cited by
-
Characteristics and survival outcomes in pediatric patients with spinal chordomas: insights from the National Cancer Database and review of the literature.J Neurooncol. 2025 Apr;172(2):397-405. doi: 10.1007/s11060-024-04921-x. Epub 2025 Jan 2. J Neurooncol. 2025. PMID: 39747717 Free PMC article. Review.
-
Risk calculator for long-term survival prediction of spinal chordoma versus chondrosarcoma: a nationwide analysis.J Neurooncol. 2025 Sep;174(2):511-525. doi: 10.1007/s11060-025-05063-4. Epub 2025 Apr 28. J Neurooncol. 2025. PMID: 40295452
-
Poorly Differentiated Aggressive Sacral Chordoma With Upfront Lung Metastases in a Child-A Case Report.Clin Case Rep. 2025 Aug 1;13(8):e70738. doi: 10.1002/ccr3.70738. eCollection 2025 Aug. Clin Case Rep. 2025. PMID: 40756092 Free PMC article.
-
Impact of proton versus photon radiotherapy on overall survival in the management of spinal chordoma and mortality risk prediction: a nationwide analysis.J Neurooncol. 2025 Jun 25. doi: 10.1007/s11060-025-05104-y. Online ahead of print. J Neurooncol. 2025. PMID: 40563064
-
Multidisciplinary En-Bloc Resection of Sacral Chordoma: A Narrative Review and Illustrative Case.J Clin Med. 2025 Jun 24;14(13):4480. doi: 10.3390/jcm14134480. J Clin Med. 2025. PMID: 40648854 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources